3BBLACKBIO1,440.00

3B Blackbio Dx Limited

· Pharma & Health
₹ CrorePeersHEALTHXSURAKSHAKRSNAANEPHROPLUS
Comp Set
In ₹ Crore except Per Share
Latest Annual
3BBLACKBIO
FY25
HEALTHX
FY26
SURAKSHA
FY26
KRSNAA
FY26
Peer
Median
Valuation — at last close
P/E824.32×52.78×18.00×52.78×
P/B1.27×6.98×1.86×1.86×
EV/EBITDA17.79×11.01×14.40×
Market Cap₹970 Cr₹1,699 Cr₹1,828 Cr₹1,699 Cr
Growth
Revenue CAGR 3Y8.26%16.63%12.45%
Revenue CAGR 5Y19.20%19.20%
Net Income CAGR 3Y17.76%17.76%
Revenue YoY (latest Q)49.73%20.75%22.05%22.05%
Net Income YoY (latest Q)-92.53%40.00%-19.34%-19.34%
Profitability
EBITDA Margin55.07%-3.95%30.73%27.42%27.42% +101%
Net Income Margin52.53%-0.11%10.12%13.13%10.12% +419%
Return on Common Equity17.43%0.15%13.22%10.35%10.35% +68%
Return on Capital Employed17.57%13.89%7.84%10.87% +62%
Return on Assets16.01%-0.15%7.01%5.56%5.56% +188%
Credit & Quality
Total Debt/Equity0.00×0.01×0.55×0.28× -100%
Interest Coverage506.18×-75.12×4.30×3.53×3.53× +14239%
Scale — latest FY
Revenue / Total Income₹90.5 Cr₹1,319 Cr₹310 Cr₹773 Cr₹773 Cr -88%
Net Income₹47.6 Cr−₹1.4 Cr₹31.4 Cr₹101 Cr₹31.4 Cr +51%
Total Assets₹297 Cr₹936 Cr₹448 Cr₹1,824 Cr₹936 Cr -68%
EPS₹0.37₹6.18₹31.3₹6.18
Book Value per Share₹240.57₹46.75₹302.23₹240.57
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.